<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02508012</url>
  </required_header>
  <id_info>
    <org_study_id>9535</org_study_id>
    <nct_id>NCT02508012</nct_id>
  </id_info>
  <brief_title>Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases</brief_title>
  <acronym>ATAIM</acronym>
  <official_title>Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF Agents in the Management of Patients With Inflammatory Bowel Disease Treated With Anti-TNFalpha Biotherapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of the medical information of Montpellier</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Since their appearance more than a decade ago, anti-tumor necrosis factor (TNF) inhibitors
      have demonstrated beneficial activity in the treatment of inflammatory bowel diseases (IBD).
      However, more than one-third of patients present primary resistance, and one more third
      become resistant over time. One of the main factors associated with loss of response is the
      immunogenicity of anti-TNF biologics leading to the production of antibodies targetting the
      TNF inhibitor, namely anti-drug antibodies (ADAbs), that accelerate drug elimination from the
      serum and decrease its therapeutic activity. In this study the investigators propose a
      medico-economic evaluation of the mesurement of anti-TNF agents and anti-drug antibodies
      serum concentrations in the management of patients with inflammatory bowel disease treated
      with anti-TNFalpha inhibitors. 280 patients with Crohn's disease (CD) or ulcerative colitis
      (UC) will be included and randomized in 2 groups with or without drug and ADAbs monitoring.
      In the monitored group, in case of loss of response, the clinician will use biological
      informations to adapt the treatment following a simple treatment algorithm. In the
      unmonitored group, drug and ADAbs measurements will not be transmitted to the clinician.
      Clinical and economical benefits of the biological monitoring will be evaluated after a
      follow-up period of two years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      280 patients with Crohn's disease (CD) or ulcerative colitis (UC) will be recruted in 13
      french centers and randomized in 2 groups with or without drug and ADAbs monitoring.

      Anti-TNF inhibitors and ADAbs will be simultaneously measured in the patients serum by ELISA
      (LisaTracker - Theradiag) at weeks 6 and 24, months 4, 8, 12, 16, 20 and 24.

      In the unmonitored group, drug and ADAbs measurements will not be transmitted to the
      clinician.

      In the monitored group, in case of loss of response the clinician will use immunomonitoring
      data to adapt the treatment following a simple treatment algorithm:

        -  loss of response with therapeutic serum trough level of anti-TNF switch to another
           biologic

        -  loss of response with subtherapeutic serum trough level of anti-TNF but without
           dectectable ADAbs increase doses and/or shorten interval between infusions

        -  loss of rsponse with subtherapeutic serum trough level of anti-TNF and dectectable ADAbs
           switch to another anti-TNF if inefficient switch to another biologic.

      Clinical and economical benefits of the biological monitoring will be evaluated after a
      follow-up period of two years:

        -  primary outcome: Cost-utility analysis of the immunomonitoring strategy using
           incremental cost effectivness ratio

        -  secondary outcome: Evaluation of the quality of life (IBDQ score)
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cost-utility analysis of the immunomonitoring strategy</measure>
    <time_frame>2 years</time_frame>
    <description>incremental cost-effectiveness ratio</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>2 years</time_frame>
    <description>IBDQ score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Crohn's Disease</condition>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Immuno monitoring</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>in case of loss of response, the clinician uses immunomonitoring data to adapt the treatment following a treatment algorithm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No immuno monitoring</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>in case of loss of response, immunomonitoring data are not transmit to the clinician who adapts the treatment with classical biological informations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Immuno monitoring</intervention_name>
    <description>treatment optimization</description>
    <arm_group_label>Immuno monitoring</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with Crohn's disease or ulcerative colitis

          -  Treated with anti-TNF

        Exclusion Criteria:

          -  anti-TNF contraindication

          -  Previous treatment with anti-TNF
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thierry VINCENT, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of immunology in Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thierry VINCENT, MD, PhD</last_name>
    <phone>04.67.33.71.35</phone>
    <email>t-vincent@chu-montpellier.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University hospital</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thierry VINCENT, MD, PhD</last_name>
      <phone>04.67.33.71.35</phone>
      <email>t-vincent@chu-montpellier.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003 Feb 13;348(7):601-8.</citation>
    <PMID>12584368</PMID>
  </reference>
  <reference>
    <citation>Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans BA, Tak PP, Wolbink GJ. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 2007 Jul;66(7):921-6. Epub 2007 Feb 14.</citation>
    <PMID>17301106</PMID>
  </reference>
  <reference>
    <citation>de Vries MK, Brouwer E, van der Horst-Bruinsma IE, Spoorenberg A, van Denderen JC, Jamnitski A, Nurmohamed MT, Dijkmans BA, Aarden LA, Wolbink GJ. Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation. Ann Rheum Dis. 2009 Nov;68(11):1787-8. doi: 10.1136/ard.2009.109702.</citation>
    <PMID>19822712</PMID>
  </reference>
  <reference>
    <citation>Lecluse LL, Driessen RJ, Spuls PI, de Jong EM, Stapel SO, van Doorn MB, Bos JD, Wolbink GJ. Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol. 2010 Feb;146(2):127-32. doi: 10.1001/archdermatol.2009.347.</citation>
    <PMID>20157022</PMID>
  </reference>
  <reference>
    <citation>Ben-Horin S, Yavzori M, Katz L, Kopylov U, Picard O, Fudim E, Coscas D, Bar-Meir S, Goldstein I, Chowers Y. The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut. 2011 Jan;60(1):41-8. doi: 10.1136/gut.2009.201533. Epub 2010 Jun 2.</citation>
    <PMID>20519742</PMID>
  </reference>
  <reference>
    <citation>Karmiris K, Paintaud G, Noman M, Magdelaine-Beuzelin C, Ferrante M, Degenne D, Claes K, Coopman T, Van Schuerbeek N, Van Assche G, Vermeire S, Rutgeerts P. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology. 2009 Nov;137(5):1628-40. doi: 10.1053/j.gastro.2009.07.062. Epub 2009 Aug 5.</citation>
    <PMID>19664627</PMID>
  </reference>
  <reference>
    <citation>Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol. 2013 Jan;108(1):40-7; quiz 48. doi: 10.1038/ajg.2012.363. Epub 2012 Nov 13. Review.</citation>
    <PMID>23147525</PMID>
  </reference>
  <reference>
    <citation>Vande Casteele N, Gils A, Singh S, Ohrmund L, Hauenstein S, Rutgeerts P, Vermeire S. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol. 2013 Jun;108(6):962-71. doi: 10.1038/ajg.2013.12. Epub 2013 Feb 19.</citation>
    <PMID>23419382</PMID>
  </reference>
  <reference>
    <citation>Steenholdt C, Svenson M, Bendtzen K, Thomsen OØ, Brynskov J, Ainsworth MA. Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2011 Jul;34(1):51-8. doi: 10.1111/j.1365-2036.2011.04682.x. Epub 2011 May 3.</citation>
    <PMID>21535447</PMID>
  </reference>
  <reference>
    <citation>Afif W, Loftus EV Jr, Faubion WA, Kane SV, Bruining DH, Hanson KA, Sandborn WJ. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010 May;105(5):1133-9. doi: 10.1038/ajg.2010.9. Epub 2010 Feb 9.</citation>
    <PMID>20145610</PMID>
  </reference>
  <reference>
    <citation>Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, Dijkmans BA, Aarden L, Wolbink GJ. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011 Apr 13;305(14):1460-8. doi: 10.1001/jama.2011.406.</citation>
    <PMID>21486979</PMID>
  </reference>
  <reference>
    <citation>Steenholdt C, Brynskov J, Thomsen OØ, Munck LK, Fallingborg J, Christensen LA, Pedersen G, Kjeldsen J, Jacobsen BA, Oxholm AS, Kjellberg J, Bendtzen K, Ainsworth MA. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut. 2014 Jun;63(6):919-27. doi: 10.1136/gutjnl-2013-305279. Epub 2013 Jul 22.</citation>
    <PMID>23878167</PMID>
  </reference>
  <reference>
    <citation>Velayos FS, Kahn JG, Sandborn WJ, Feagan BG. A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab. Clin Gastroenterol Hepatol. 2013 Jun;11(6):654-66. doi: 10.1016/j.cgh.2012.12.035. Epub 2013 Jan 26.</citation>
    <PMID>23357488</PMID>
  </reference>
  <reference>
    <citation>Paul S, Del Tedesco E, Marotte H, Rinaudo-Gaujous M, Moreau A, Phelip JM, Genin C, Peyrin-Biroulet L, Roblin X. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis. 2013 Nov;19(12):2568-76. doi: 10.1097/MIB.0b013e3182a77b41.</citation>
    <PMID>24013361</PMID>
  </reference>
  <reference>
    <citation>Roblin X, Marotte H, Rinaudo M, Del Tedesco E, Moreau A, Phelip JM, Genin C, Peyrin-Biroulet L, Paul S. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2014 Jan;12(1):80-84.e2. doi: 10.1016/j.cgh.2013.07.010. Epub 2013 Jul 23.</citation>
    <PMID>23891927</PMID>
  </reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2015</study_first_submitted>
  <study_first_submitted_qc>July 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2015</study_first_posted>
  <last_update_submitted>July 23, 2015</last_update_submitted>
  <last_update_submitted_qc>July 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anti-TNF</keyword>
  <keyword>Immuno-monitoring</keyword>
  <keyword>Anti-drug antibody (ADAb)</keyword>
  <keyword>Inflammatory bowel disease (IBD)</keyword>
  <keyword>Crohn's disease</keyword>
  <keyword>Ulcerative colitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

